Research programme: bispecific antibodies - Duality Biologics
Alternative Names: Bispecific antibodies - Duality BiologicsLatest Information Update: 02 Jun 2021
At a glance
- Originator Duality Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer